Influence of AR on cumulative incidence of relapse, death and OS in first CR according to applied treatment strategy
| . | Distribution of FLT3-ITD AR intervals, no. (%) . | . | |||
|---|---|---|---|---|---|
| Outcome . | First . | Second . | Third . | Fourth . | P value . |
| CTX/autoHSCT (no. of patients) | 45 | 35 | 35 | 23 | |
| CIR after 3 years (SE) | 62 (7.4) | 67 (8.3) | 77 (7.4) | 78 (9.1) | .037 |
| CID after 3 years (SE ) | 6.7 (3.8) | 3 (3.1) | 11.4 (5.6) | 0 | .15 |
| OS after 3 years (95% CI) | 40 (28-57) | 53 (39-73) | 21 (11-41) | 30 (16-56) | .02 |
| Allogeneic HSCT (no. of patients) | 21 | 28 | 21 | 23 | |
| CIR after 3 years (SE) | 38 (11.0) | 36 (9.3) | 14 (7.8) | 30 (10.0) | .20 |
| CID after 3 years (SE) | 14 (7.9) | 14 (6.8) | 29 (10.5) | 30 (10.0) | .45 |
| OS after 3 years (95% CI) | 56 (38-82) | 57 (41-79) | 56 (39-83) | 44 (27-69) | .60 |
| . | Distribution of FLT3-ITD AR intervals, no. (%) . | . | |||
|---|---|---|---|---|---|
| Outcome . | First . | Second . | Third . | Fourth . | P value . |
| CTX/autoHSCT (no. of patients) | 45 | 35 | 35 | 23 | |
| CIR after 3 years (SE) | 62 (7.4) | 67 (8.3) | 77 (7.4) | 78 (9.1) | .037 |
| CID after 3 years (SE ) | 6.7 (3.8) | 3 (3.1) | 11.4 (5.6) | 0 | .15 |
| OS after 3 years (95% CI) | 40 (28-57) | 53 (39-73) | 21 (11-41) | 30 (16-56) | .02 |
| Allogeneic HSCT (no. of patients) | 21 | 28 | 21 | 23 | |
| CIR after 3 years (SE) | 38 (11.0) | 36 (9.3) | 14 (7.8) | 30 (10.0) | .20 |
| CID after 3 years (SE) | 14 (7.9) | 14 (6.8) | 29 (10.5) | 30 (10.0) | .45 |
| OS after 3 years (95% CI) | 56 (38-82) | 57 (41-79) | 56 (39-83) | 44 (27-69) | .60 |